MTOR and ganglioneuroma: These findings suggest that mTOR inhibitors may represent a promising therapeutic strategy for the treatment of ganglioneuromas.[40] If subsequent clinical trials can confirm that mTOR inhibitors can inhibit the growth of GN and reduce the volume of GN tumors in the human body, then targeted therapy to reduce tumor volume before surgery on large-volume GN, while reducing adhesion of the tumor to surrounding tissue, will greatly reduce surgical risks.